You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY21 is not expected to be complete until September, 2022.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Restoring Beta-lactam efficacy against methicillin-resistant Staphylococci

    SBC: Prokaryotics, Inc.            Topic: NIAID

    Methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE) are a major cause of bloodstream infections in the hospital and in the community. Indeed, MRSA remains the second leading cause of mortality by drug-resistant bacterial pathogens in the USA. Although two mechanistically novel antibiotic classes exist to treat such infections (Daptomycin; ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Malarial Retinopathy Screening System for Improved Diagnosis of Cerebral Malaria

    SBC: VisionQuest Biomedical Inc            Topic: NIAID

    Summary Cerebral malaria (CM) is a life-threatening clinical syndrome associated with malarial infection. Annually, malaria affects more than 200 million people and claims the lives of over 440,000 people worldwide, mostly African children. As a consequence of the high incidence of CM, it is often misdiagnosed for other pathologies with similar symptoms, leading to a high false positive rate for C ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Protein therapeutic to facilitate healing of chronic wounds.

    SBC: TRIM-EDICINE, INC.            Topic: 300

    Project Summary This proposal builds upon the advances from the SBIR-Phase I program (R43GM123887), targeting the development of recombinant human MG53 (rhMG53), a novel tissue repair protein, as a topical therapeutic agent to facilitate healing of chronic wounds. Wound care represents a challenging problem to the public health, as no effective treatments for chronic non-healing wounds are availab ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  4. High-Throughput Spheroid Screening Platform

    SBC: BennuBio Inc            Topic: 400

    PROJECT SUMMARYThis proposal will develop the High-Throughput Spheroid Screening Platform (HTSSP) to create an entirely new tool to study cell-cell interactions and microenvironmental stresses that occur in tissues and tumors. Such interactions are critical in the pharmaceutical response of cells within tissues, but current methods do not allow high throughput screening (HTS) of cellular responses ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Rapid and Effective Localized Neurovascular Cooling Using the Khione Insulative Catheter

    SBC: Tom L Merrill            Topic: 101

    Project Summary Stroke is the 5th leading cause of death and number one cause of adult disability in the United States. The primary goal of acute ischemic stroke (AIS) treatment is quickly restoring blood perfusion. However, studies have shown that this return of blood flow, while necessary, can also cause damage to local tissue leading to poor patient outcomes. Therapeutic hypothermia (TH) has be ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Performance Evaluation of a non-Degradable Synthetic Device for Chondral and Osteochondral Defects of the Knee

    SBC: Hydro-Gen LLC            Topic: NIAMS

    Injury to joints can lead to painful defects in articular cartilage and the underlying bone, which adversely affect the function and biological health of the entire joint. Current solutions for cartilage (chondral) and cartilage-and- bone (osteochondral) defects, are unreliable, are technically challenging, and often require multiple procedures. A surgeon-engineer-biologist team at Hospital for Sp ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  7. 3D-Printed Superhydrophobic-Tipped Optical Fiber for Targeted Periodontal Photodynamic Therapy

    SBC: SingletO2 Therapeutics LLC            Topic: NIDCR

    Eradication of bacteria located in periodontal pockets presents a daunting challenge to dentists and oral care professionals. The problem is significant; severe periodontitis is the 6th most prevalent disease worldwide with over 743 million people affected. The global cost of lost productivity from severe periodontitis is estimated to be $54 billion USD/year. Antibiotics with scaling and root plan ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Laboratory Bench-Top EXAFS with STJ Spectrometer

    SBC: STAR CRYOELECTRONICS LLC            Topic: 400

    PROJECT SUMMARY Extended X-ray absorption fine structure (EXAFS) spectroscopy is a technique that gives element-specific structural and chemical information about molecules. An enormous advantage of EXAFS spectroscopy is that it is readily applied to many different kinds of sample, including, solutions, powders, slurries, and animal tissues. Current EXAFS instruments require bright X-ray beams fro ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  9. A Novel Immunotherapy Targeting Cancer Stem Cells for the Treatment of Triple-Negative Breast Cancer

    SBC: Agilvax, Inc.            Topic: 102

    Agilvax’s AX09 is an Immunotherapy for Triple-Negative Breast Cancer: Agilvax is developing cancer immunotherapies and vaccines with its proprietary virus-like-particle (VLP) platform technology. Agilvax’s lead product, AX09, is an immunotherapy for triple-negative breast cancer (TNBC) targeting cancer stem cells (CSC) that is designed for use in combination with existing and emerging therapie ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Development of a novel agent to treat antimicrobial resistant Neisseria gonorrhoeae

    SBC: Prokaryotics, Inc.            Topic: R

    The WHO estimates gonorrhea infections occur in 78 million people globally every year. The extensive spread of antimicrobial resistant Ng has prompted the CDC to designate it as an Urgent Threat pathogen. Alarmingly, resistance is now emerging to the remaining current standard of care (SOC) dual therapy of ceftriaxone (CRO) and azithromycin (AZM). Despite this global health crisis, few new therape ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government